Literature DB >> 32420282

Identifying the relevant population for neoadjuvant chemo-hormonal therapy combined with radical prostatectomy.

Géraldine Pignot1, Jochen Walz1.   

Abstract

Year:  2020        PMID： 32420282      PMCID： PMC7225477          DOI： 10.21037/gs.2019.12.22

Source DB:  PubMed          Journal:  Gland Surg        ISSN： 2227-684X


× No keyword cloud information.
  14 in total

1.  Phase II trial of neoadjuvant docetaxel before radical prostatectomy for locally advanced prostate cancer.

Authors:  Robert Dreicer; Cristina Magi-Galluzzi; Ming Zhou; Jason Rothaermel; Alwyn Reuther; James Ulchaker; Craig Zippe; Amr Fergany; Eric A Klein
Journal:  Urology       Date:  2004-06       Impact factor: 2.649

2.  Neoadjuvant chemohormonal therapy combined with radical prostatectomy and extended PLND for very high risk locally advanced prostate cancer: A retrospective comparative study.

Authors:  Jiahua Pan; Chenfei Chi; Hongyang Qian; Yinjie Zhu; Xiaoguang Shao; Jianjun Sha; Fan Xu; Yanqing Wang; Robert J Karnes; Baijun Dong; Wei Xue
Journal:  Urol Oncol       Date:  2019-08-27       Impact factor: 3.498

3.  Poorly differentiated prostate cancer treated with radical prostatectomy: long-term outcome and incidence of pathological downgrading.

Authors:  John F Donohue; Fernando J Bianco; Kentaro Kuroiwa; Andrew J Vickers; Thomas M Wheeler; Peter T Scardino; Victor A Reuter; James A Eastham
Journal:  J Urol       Date:  2006-09       Impact factor: 7.450

4.  Impact of Therapy on Genomics and Transcriptomics in High-Risk Prostate Cancer Treated with Neoadjuvant Docetaxel and Androgen Deprivation Therapy.

Authors:  Himisha Beltran; Alexander W Wyatt; Edmund C Chedgy; Adam Donoghue; Matti Annala; Evan W Warner; Kevin Beja; Michael Sigouros; Fan Mo; Ladan Fazli; Colin C Collins; James Eastham; Michael Morris; Mary-Ellen Taplin; Andrea Sboner; Susan Halabi; Martin E Gleave
Journal:  Clin Cancer Res       Date:  2017-08-25       Impact factor: 12.531

Review 5.  Chemotherapy and novel therapeutics before radical prostatectomy for high-risk clinically localized prostate cancer.

Authors:  Eugene K Cha; James A Eastham
Journal:  Urol Oncol       Date:  2015-01-14       Impact factor: 3.498

6.  Neoadjuvant docetaxel before radical prostatectomy in patients with high-risk localized prostate cancer.

Authors:  Phillip G Febbo; Jerome P Richie; Daniel J George; Massimo Loda; Judith Manola; Sridhar Shankar; Agnieska Szot Barnes; Clare Tempany; William Catalona; Philip W Kantoff; William K Oh
Journal:  Clin Cancer Res       Date:  2005-07-15       Impact factor: 12.531

Review 7.  A systematic review and meta-analysis of randomised trials of neo-adjuvant hormone therapy for localised and locally advanced prostate carcinoma.

Authors:  M D Shelley; S Kumar; T Wilt; J Staffurth; B Coles; M D Mason
Journal:  Cancer Treat Rev       Date:  2008-10-15       Impact factor: 12.111

Review 8.  Systemic treatments for high-risk localized prostate cancer.

Authors:  Géraldine Pignot; Denis Maillet; Emmanuel Gross; Philippe Barthelemy; Jean-Baptiste Beauval; Friederike Constans-Schlurmann; Yohann Loriot; Guillaume Ploussard; Paul Sargos; Marc-Olivier Timsit; Sébastien Vincendeau; Gilles Pasticier; Delphine Borchiellini
Journal:  Nat Rev Urol       Date:  2018-08       Impact factor: 14.432

Review 9.  Rationale for and review of neoadjuvant therapy prior to radical prostatectomy for patients with high-risk prostate cancer.

Authors:  Rana R McKay; Toni K Choueiri; Mary-Ellen Taplin
Journal:  Drugs       Date:  2013-09       Impact factor: 9.546

Review 10.  Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data.

Authors:  Claire L Vale; Sarah Burdett; Larysa H M Rydzewska; Laurence Albiges; Noel W Clarke; David Fisher; Karim Fizazi; Gwenaelle Gravis; Nicholas D James; Malcolm D Mason; Mahesh K B Parmar; Christopher J Sweeney; Matthew R Sydes; Bertrand Tombal; Jayne F Tierney
Journal:  Lancet Oncol       Date:  2015-12-21       Impact factor: 41.316
View more
  1 in total

1.  Neoadjuvant Androgen Deprivation Therapy Effects on Perioperative Outcomes Prior to Radical Prostatectomy: Eleven Years of Experiences at Ramathibodi Hospital.

Authors:  Premsant Sangkum; Kun Sirisopana; Pocharapong Jenjitranant; Kittinut Kijvikai; Suthep Pacharatakul; Charoen Leenanupunth; Wachira Kochakarn; Wisoot Kongchareonsombat
Journal:  Res Rep Urol       Date:  2021-06-01
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.